Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ISRCTN11269259) titled 'A 2-part study to investigate the safety, tolerability and effect of MB272 in healthy volunteers' on June 16.
Study Type: Interventional
Study Design:
A two-part first-in-human interventional randomized controlled trial (Other, Safety)
Primary Sponsor: Gilead Sciences (United States)
Condition:
Healthy volunteers
Other
Intervention:
This was a Phase 1, first-in-human, randomised, double-blind study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and immunogenicity of different dose levels of GS-0272, a monoclonal antibody targeting immune cell receptors expressed on B- and T-cells, in health...